4. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy 译：动态监测循环肿瘤DNA 揭示接受 CAR T 细胞治疗的复发或难治性大 B 细胞淋巴瘤患者的结果和基因组变化 作者列表:Zou H;L...
TREATMENT OF INTESTINAL T CELL LYMPHOMA WITH TANOVEA CA1 IN A 12-YEAR-OLD GOLDEN RETRIEVERThis case report highlights Tanovea CA1 as an effective treatment for a patient who had failed multiple chemotherapy protocols for the treatment of lymphoma. When the gold standard CHOP protocol and rescue...
Novartis is continuing studies of tisagenlecleucel in DLBCL, ALL and relapsed or refractory follicular lymphoma. Other CAR T-cell therapies in Novartis’s pipeline include targeting CD19 in CLL, anti-B-cell maturation antigen (BCMA) CAR T for multiple myeloma, anti-EGFRvIII ...
Our data suggest that such inhibitors may be efficacious and sufficient in treatment of lymphoma and leukemia by direct inhibition of DNA synthesis. In conclusion, we propose a model where c-Myc-dependent Txnip downregulation by T-cell activation is critical for release of active Trx1 that in ...
YOLO also predicts the bounding box coordinates relative to cell26. To improve the accuracy of the predictions, YOLO uses a technique called anchor boxes, which are predefined boxes of different sizes and aspect ratios. Each anchor box is associated with a particular cell and is used to predict...
In its secreted water-soluble form, LtxA has been demonstrated to bind to an integrin receptor, lymphocyte function-associated antigen-1 (LFA-1) [14–16], which is only expressed by human white blood cells, an interaction that provides the toxin with its cell type specificity, in addition ...
MTT assay was used to evaluate the effect of these compounds on different human breast cancer cell lines, including MCF-7, MDA-MB-231 and T-47D cells (Table 1). Ap was not active against all breast cancer cells at 88 µM for 72 h treatment. DAp exhibited the most potent cytotoxic ...
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituxima... PURPOSE: The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage ...
2507 Accesses 10 Altmetric 1 Mention Explore all metrics Abstract Introduction Chimeric antigen receptor T-cell (CAR T) therapies have transformed diffuse large B-cell lymphoma (DLBCL) treatment. It is important to better understand their use in Medicare Fee-for-Service (FFS) patients, who often ...
10, 2686 (2019). PubMed PubMed Central Google Scholar Bentebibel, S. E., Schmitt, N., Banchereau, J. & Ueno, H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc. Natl. Acad. Sci. USA. 108, E488–...